Susan Ziolkowski United States

Institution

Day 1 - Sunday April 14, 2024

Time Session
12:15 p.m.
1:15 p.m.
Onconephrology: Various Flavors of AKI
CHAL02
JavierDe Arteaga Chairperson javierdearteaga@gmail.comArgentinaHospital Privado Universitario de Cordoba. Catholic University from Cordoba
KarinaSoto Chairperson ksoto.nefro@gmail.comPortugalCentro Hospitalar de Setubal, EPE and CEDOC Universidade Nova de Lisboa
SandraHerrmann Chairperson herrmann.sandra@mayo.eduUnited StatesMayo Clinic
  • AKI-related Cancer and Cancer Treatment-related TMA
    ClaraGarcía Carro Speaker claragarciacarro@hotmail.comSpainSan Carlos Clinical Hospital (Madrid, Spain)
  • AKI Related to Cancer Immunotherapy: Can Biomarkers Help?
    SebastianLapman Speaker lapseba@yahoo.com.arArgentina
  • Magnesium and AKI: Is There a Connection? From Bench to Bedside - What We Can Learn from Onconephrology
    JolantaMalyszko Speaker PolandMedical University of Warsaw, Poland
  • Q and A
Hall E
3 p.m.
4 p.m.
Cardiorenal Syndrome: Updates in the Pathophysiology and State-of-the-Art Treatment
IK01
FelipeInserra Chairperson felipe.inserra@gmail.comArgentina
YelenaDrexler Chairperson yrd6@miami.eduUnited StatesUniversity of Miami Miller School of Medicine
  • New Insights into the Mechanisms of Kidney Injury in the CRS
    WendyMccallum Speaker wmccallum@tuftsmedicalcenter.orgUnited States
  • Novel Pharmacological Treatments of the CRS
    MarkSarnak Speaker msarnak@tuftsmedicalcenter.orgUnited StatesTufts Medical Center
  • Device-related Treatment for CRS
    ClaudioRonco Speaker cronco@goldnet.itItalyInternational Renal Research Institute of Vicenza
  • Q and A
Hall D
New Tools to Study Kidney Disease
SK02
RafaelMaldonado Chairperson ramaldonado@gmail.comArgentina
ReikoInagi Chairperson JapanThe University of Tokyo Graduate School of Medicine
  • Understanding Glomerular Damage: From Spatial Transcriptomics to Chip Technology
    LauraPerin Speaker LPerin@chla.usc.eduUnited States
  • Spatial Metabolomics of Kidney Disease
    TonRabelink Speaker a.j.rabelink@lumc.nlNetherlandsLUMC
  • Constructing an Epigenetic Network for Diabetic Nephropathy
    Sam El-Osta Speaker sam.el-osta@baker.edu.auAustraliaBaker Heart and Diabetes Institute
  • Q and A
Hall E
4:30 p.m.
5:30 p.m.
New Developments in CKD Epidemiology Research
IK1001
MaartenTaal Chairperson United KingdomUniversity of Nottingham
RobertoPecoits Filho Chairperson United StatesArbor Research Collaborative for Health
  • Big Data Lab
    LAB-01
  • Patient-reported Outcome Measures: How Do Patients Experience CKD?
    AdeeraLevin Speaker CanadaUniversity of British Columbia and Providence Health Care
  • Trial Simulation Using Observational Data
    AngeloKaraboyas Speaker angelo.karaboyas@arborresearch.orgUnited StatesArbor Research Collaborative for Health
  • Using Routinely Collected Big Datasets for Clinical Research in CKD: Opportunities and Challenges
    DorotheaNitsch Speaker United KingdomLondon School of Hygiene & Tropical Medicine
  • Q and A
Hall C4
5 p.m.
5:30 p.m.
Glomerular Disease Jeopardy
SPOT-09
ArennJauhal Spotlight Chairperson Arenn.Jauhal@uhn.caCanada
PaulaParnizari Croci Spotlight Chairperson paulaparnizari@gmail.comUruguay
RichardLafayette Spotlight Chairperson czar@stanford.eduUnited States
Spotlight Stage 1 (exhibition hall)

Day 2 - Monday April 15, 2024

Time Session
4:30 p.m.
5:30 p.m.
Paraproteinemia and the Kidney
CHAL05
CarolineLamarche Chairperson caroline.lamarche.1@umontreal.caCanadaUniversité de Montréal
Gustavo CristianGreloni Chairperson gustavo.greloni@hospitalitaliano.org.arArgentina
  • MGRS: Should All Forms Need Clonal Therapy?
    FrankBridoux Speaker f.bridoux@chu-poitiers.frFranceDepartment of Nephrology and French Reference Center for AL amyloidosis and MGRS, University Hospital, Poitiers, France
  • Renal Amyloidosis: What Is New?
    Veronica Torres CostaSilva Speaker veronica.torres@hc.fm.usp.brBrazilSão Paulo State Cancer Institute - University of São Paulo
  • Can We Perform a Transplant in Patients with Myeloma and Amyloidosis?
    SabineKaram Speaker United StatesUniversity of Minnesota
  • Q and A
Hall A

Day 3 - Tuesday April 16, 2024

Time Session
9 a.m.
10:30 a.m.
Clinical Management of Glomerulonephritis (GN)
SK06
Juan ManuelMejia Vilet Chairperson jmmejia@hotmail.comMexicoInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
ValeriaAlberton Chairperson vgalberton@gmail.comArgentinaHospital Fernandez/ Hospital El Cruce
  • Updates on IgAN Management
    HernánTrimarchi Speaker ArgentinaHOSPITAL BRITÁNICO DE BUENOS AIRES
  • Membranous GN Classification and Management
    PierreRonco Speaker FranceHôpital Tenon
  • MPGN Updates
    SanjeevSethi Speaker United StatesMayo Clinic
  • Managing Vasculitis
    RobertaFenoglio Speaker roberta.fenoglio@unito.itItalyOspedale San Giovanni Bosco
  • Q and A
Hall A
12:30 p.m.
1:30 p.m.
Hot Debate in CKD Hypertension Management: Targeting Systolic BP Below 120?
IK05
MarceloOrías Chairperson marcelo.orias@gmail.comArgentina
MarkSarnak Chairperson msarnak@tuftsmedicalcenter.orgUnited StatesTufts Medical Center
  • Hot Debate in CKD Hypertension Management: Targeting Systolic BP Below 120? - PROS
    TaraChang Speaker tichang@stanford.eduUnited StatesStanford University
  • Hot Debate in CKD Hypertension Management: Targeting Systolic BP Below 120? - CONS
    JordanaCohen Speaker jco@pennmedicine.upenn.eduUnited StatesUniversity of Pennsylvania
Hall A